Neuronox is a botulinum toxin type A complex (100 Units) pharmaceutical manufactured by Medy-Tox Inc. and officially launched in Korea in 2006. Following much research on biological, biochemical, immunological, and toxicity aspects, botulinum toxin type A has been developed as a biopharmaceutical product.
Neuronox is indicated for the treatment of benign essential blepharospasm in patients 18 years of age and older. Botulinum toxin is injected into muscles and works by blocking nerve impulses in the injected areas. This reduces muscle activity that causes facial wrinkles.